KLEIN JOSEPH III

Director Joseph Klein III sold 22,321 shares for $1.7M (blended avg $75.55), reducing stake by 67% to 11.0K shares

Director Joseph Klein III executed 2 separate sales on 2026-04-01, totaling 22,321 shares for $1,686,301.88 at an average price of $75.55 per share, reducing his holdings from 33,335 to 11,014 shares (-67.0%). The timing is noteworthy: the stock now trades at $74.79, down 4.9% in the past 30 days and 6.1% over 90 days from transaction date. Examining his same-ticker history at IONS reveals a pattern of recent selling activity in early March 2026 that has each shown negative 30-day returns (-5.5%, -6.5%, -7.5%), and his 0 of 2 measurable 90-day outcomes on prior IONS sells were well-timed (stock fell after sale). However, his cross-ticker track record is mixed: 5 prior sells averaged +35.5% 90-day return, indicating most have been poorly timed on other stocks. The company remains unprofitable (net income $-128.6M against $156.7M quarterly revenue) despite strong 33.8% annual revenue growth, which may provide context for insider share reduction decisions.

Director Klein sells 21,332 shares at $79.51 avg, reduces stake by 65.9% to 11,014 shares

Joseph Klein III, a Director, executed 3 separate sales totaling 21,332 shares for $1,696,181.37 on 2026-03-03, reducing his holdings from 32,346 shares to 11,014 shares (a 65.9% reduction in position size). The sales occurred at a blended average price of $79.51, which is above the current price of $75.16, and materially above the 52-week low of $25.51 but below the 52-week high of $86.50. At IONS specifically, Klein's 2 prior sales in September 2025 posted identical 30-day and 90-day returns (+15.2% and +35.5% respectively), indicating the stock rose after those sales—a pattern that, if continued here, would mean this sale was poorly timed relative to subsequent price action. The company is unprofitable (full-year net income negative) despite strong revenue growth of 33.8% year-over-year, creating a mixed fundamental backdrop where director stock sales of this magnitude warrant tracking against near-term earnings and operational milestones.

Director Joseph Klein III sold 28,000 shares of IONS at $60.00 for $1.7M, exiting full position, as stock near 52-week high.

Director Joseph Klein III sold his entire 28,000-share holding of IONS at $60.00 on 2025-09-03, just 49 basis points below the 52-week high of $60.49. The sale occurred within a context of strong recent momentum: the stock is up 37.9% over 30 days and 68.2% over 90 days. However, the company reported a full-year net loss in its most recent fiscal year and annual revenue declined 10.5% year-over-year, despite positive near-term quarterly revenue of $452.0M and net income of $123.6M. The director's complete exit occurs at a valuated price near the stock's ceiling, which may reflect a tactical response to elevated valuation following the recent rally, though without scheduled-trading disclosure (10b5-1) or explanation of the transaction's motivation, the reasons for the full liquidation remain opaque to investors.

Director Joseph Klein III sold entire 28,000 IONS position for $1.7M at $60.00 on 2025-09-03.

Joseph Klein III, a director at Ionis Pharmaceuticals, executed a complete liquidation of his equity stake, selling all 28,000 shares at $60.00 for a total value of $1,680,000.00 on 2025-09-03. The sale occurred near the 52-week high ($60.49), with the stock up 37.9% over the prior 30 days and 68.2% over 90 days, suggesting the transaction took place during a period of strong share price appreciation. The company's financial backdrop shows mixed signals: most recent quarter revenue of $452,049,000.00 and net income of $123,551,000.00, but annual revenue declined -10.5% year-over-year and full-year net income was negative, indicating underlying operational challenges despite the recent stock momentum. Klein's track record shows only 1 prior open-market sell across all tickers, making this complete exit a relatively infrequent action for this insider.